Program Objectives, CME, & Disclaimers

Program Objectives

Attendees of the 2020 Annual Leadership Meeting of The American Orthopaedic Association will discuss and debate, formally and informally, controversies in orthopaedic practice, science, ethics, education, economics, and social issues. Physicians will also advance their knowledge of orthopaedic surgery and science and learn new practices that can be implemented to improve patient care. 

Continuing Medical Education (CME)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Academy of Orthopaedic Surgeons and the American Orthopaedic Association. The American Academy of Orthopaedic Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

2020 VIRTUAL AOA Annual Leadership Meeting
The American Academy of Orthopaedic Surgeons designates this live activity/enduring material for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

2020 Affiliated Events

The American Academy of Orthopaedic Surgeons designates each of the following activities for the maximum of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Virtual CORD Conference: The AAOS designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™
Virtual Own the Bone Symposium: The AAOS designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™
Virtual Emerging Leaders Forum: The AAOS designates this line activitiy for a maximum of 4.5 AMA PRA Category 1 Credits™

Disclosures/Disclaimers

Disclosure 

Each Annual Meeting speaker has been asked to disclose if he or she, or a member of their immediate family, has a financial interest or other relationship with a commercial company or institution, which relates directly or indirectly to the subject of his or her presentation. 

An indication of the participant’s disclosure will appear online after his or her name, as well as the commercial company or institution that provided the support. If the participant discloses he or she does not have any financial interests or commitments, this information will also be noted. The AOA does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in the Annual Meeting. An indication of the participant’s disclosure will appear on the AOA’s website. 

FDA Disclaimer

Some drugs or medical devices demonstrated at the Annual Meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice. 

The AOA’s policy provides that “off label” uses of a device or pharmaceutical may be described in the AOA’s CME activities so long as the “off label” status of the device or pharmaceutical is also specifically disclosed (i.e. it must be disclosed that the FDA has not approved labeling the device for the described purpose). Any device or pharmaceutical is being used “off label” if the described use is not set forth on the product’s approval label.